Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approach

Br J Cancer. 2021 Aug;125(4):467-469. doi: 10.1038/s41416-021-01285-1. Epub 2021 Apr 6.

Abstract

Emerging studies have demonstrated the potential of PI3Kδ blockade as an immunotherapy for solid tumours. In pre-clinical models, we recently demonstrated that anti-LAG3 immune checkpoint blockade vastly potentiated PI3Kδ-based immunotherapy, enabling successful tumour control in all treated mice.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens, CD / immunology*
  • Class I Phosphatidylinositol 3-Kinases / immunology*
  • Drug Resistance, Neoplasm / drug effects
  • Drug Synergism
  • Humans
  • Immune Checkpoint Inhibitors / pharmacology*
  • Immune Checkpoint Inhibitors / therapeutic use
  • Immunotherapy
  • Lymphocyte Activation Gene 3 Protein
  • Mice
  • Neoplasms / drug therapy*
  • Neoplasms / immunology
  • Tumor Microenvironment
  • Xenograft Model Antitumor Assays

Substances

  • Antigens, CD
  • Immune Checkpoint Inhibitors
  • Class I Phosphatidylinositol 3-Kinases
  • PIK3CD protein, human
  • Lymphocyte Activation Gene 3 Protein